I-MAB revenue for the last year amounted to 3.89 M USD, the most of which — 3.90 M USD — came from its highest performing source at the moment, Transformational Biologics, the year earlier bringing -32.90 M USD. The greatest contribution to the revenue figure was made by China — last year it brought I-MAB 3.90 M USD, and the year before that — -32.90 M USD.